Scutellarin: pharmacological effects and therapeutic mechanisms in chronic diseases.

IF 4.4 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Frontiers in Pharmacology Pub Date : 2024-11-07 eCollection Date: 2024-01-01 DOI:10.3389/fphar.2024.1470879
Shanshan Nie, Shan Zhang, Ruipeng Wu, Yuhang Zhao, Yongxia Wang, Xinlu Wang, Mingjun Zhu, Peng Huang
{"title":"Scutellarin: pharmacological effects and therapeutic mechanisms in chronic diseases.","authors":"Shanshan Nie, Shan Zhang, Ruipeng Wu, Yuhang Zhao, Yongxia Wang, Xinlu Wang, Mingjun Zhu, Peng Huang","doi":"10.3389/fphar.2024.1470879","DOIUrl":null,"url":null,"abstract":"<p><p>Scutellarin (SCU), a flavonoid glucuronide derived from <i>Scutellaria barbata</i> and <i>Erigeron breviscapus</i>, exhibits broad pharmacological effects with promising therapeutic potential in treating various chronic diseases. It has demonstrated efficacy in modulating multiple biological pathways, including antioxidant, anti-inflammatory, anti-apoptotic, and vasodilatory mechanisms. These protective roles make SCU a valuable compound in treating chronic diseases such as cerebrovascular diseases, cardiovascular diseases, neurodegenerative disorders, and metabolic diseases. Despite its multi-targeted effects, SCU faces challenges such as low bioavailability and limited clinical data, which hinder its widespread therapeutic application. Current research supports its potential to prevent oxidative stress, reduce inflammatory responses, and enhance cell survival in cells and rats. However, more comprehensive studies are required to clarify its molecular mechanisms and to develop strategies that enhance its bioavailability for clinical use. SCU could emerge as a potent therapeutic agent for the treatment of chronic diseases with complex pathophysiological mechanisms. This review examines the current literature on Scutellarin to provide a comprehensive understanding of its pharmacological activity, mechanisms of action, and therapeutic potential in treating chronic diseases.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1470879"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578714/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1470879","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Scutellarin (SCU), a flavonoid glucuronide derived from Scutellaria barbata and Erigeron breviscapus, exhibits broad pharmacological effects with promising therapeutic potential in treating various chronic diseases. It has demonstrated efficacy in modulating multiple biological pathways, including antioxidant, anti-inflammatory, anti-apoptotic, and vasodilatory mechanisms. These protective roles make SCU a valuable compound in treating chronic diseases such as cerebrovascular diseases, cardiovascular diseases, neurodegenerative disorders, and metabolic diseases. Despite its multi-targeted effects, SCU faces challenges such as low bioavailability and limited clinical data, which hinder its widespread therapeutic application. Current research supports its potential to prevent oxidative stress, reduce inflammatory responses, and enhance cell survival in cells and rats. However, more comprehensive studies are required to clarify its molecular mechanisms and to develop strategies that enhance its bioavailability for clinical use. SCU could emerge as a potent therapeutic agent for the treatment of chronic diseases with complex pathophysiological mechanisms. This review examines the current literature on Scutellarin to provide a comprehensive understanding of its pharmacological activity, mechanisms of action, and therapeutic potential in treating chronic diseases.

黄芩苷:慢性疾病的药理作用和治疗机制。
黄芩苷(SCU)是从黄芩(Scutellaria barbata)和麦冬(Erigeron breviscapus)中提取的一种黄酮类葡萄糖醛酸苷,具有广泛的药理作用,在治疗各种慢性疾病方面具有广阔的治疗潜力。它具有调节多种生物通路的功效,包括抗氧化、抗炎、抗细胞凋亡和血管舒张机制。这些保护作用使 SCU 成为治疗脑血管疾病、心血管疾病、神经退行性疾病和代谢性疾病等慢性疾病的重要化合物。尽管具有多靶点效应,但 SCU 面临着生物利用率低和临床数据有限等挑战,这阻碍了其广泛的治疗应用。目前的研究支持其在细胞和大鼠中预防氧化应激、减少炎症反应和提高细胞存活率的潜力。不过,还需要进行更全面的研究,以明确其分子机制,并开发出提高其生物利用度的策略,以便用于临床。SCU 可能会成为一种有效的治疗药物,用于治疗病理生理机制复杂的慢性疾病。本综述研究了有关黄芩苷的现有文献,以全面了解其药理活性、作用机制以及治疗慢性疾病的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信